Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1992346 | 0.98 | BBOX1 (0.40) | BBOX1ENPP2 | |
| SCHEMBL2325773 | 0.89 | BBOX1 (0.31) | BBOX1 | |
| Hydrochloric Acid SCHEMBL1992902 | 0.88 | BBOX1 (0.31) | BBOX1 | |
| SCHEMBL12852715 | 0.77 | MEN1 (0.39) | BBOX1 | |
| SCHEMBL12852883 | 0.77 | BBOX1 (0.45) | BBOX1ENPP2 | |
| SCHEMBL2320020 | 0.76 | BBOX1 (0.41) | BBOX1ENPP2 | |
| Hydrochloric Acid SCHEMBL3250457 | 0.75 | APEX1 (0.42) | BBOX1 | |
| SCHEMBL3421065 | 0.75 | APEX1 (0.41) | — | |
| Hydrochloric Acid SCHEMBL1993252 | 0.75 | BBOX1 (0.40) | BBOX1ENPP2 | |
| SCHEMBL12852496 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2341886-B1 | ANTIMICROBIAL N-CHLORINATED COMPOSITIONS | NOVABAY PHARMACEUTICALS INC (US) | 2015-08-26 | — | — | EP | claimed |
| EP-2531026-A1 | POLYSACCHARIDE BASED ANTIMICROBIAL FORMULATIONS | NovaBay Pharmaceuticals, Inc. (US) | 2012-12-12 | — | — | EP | disclosed |
| US-8278482-B2 | Antimicrobial N-chlorinated compositions | NOVABAY PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| WO-2011097324-A1 | POLYSACCHARIDE BASED ANTIMICROBIAL FORMULATIONS | NOVABAY PHARMACEUTICALS, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
| WO-2011097324-A1 | POLYSACCHARIDE BASED ANTIMICROBIAL FORMULATIONS | NOVABAY PHARMACEUTICALS, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
| US-20110190392-A1 | Polysaccharide Based Antimicrobial Formulations | NOVABAY PHARMACEUTICALS, INC. | 2011-08-04 | — | — | US | disclosed |
| US-20100158818-A1 | ANTIMICROBIAL N-CHLORINATED COMPOSITIONS | NOVABAY PHARMACEUTICALS, INC. | 2010-06-24 | — | — | US | disclosed |
| WO-2010054269-A1 | ANTIMICROBIAL N-CHLORINATED COMPOSITIONS | NOVABAY PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100158818-A1 | ANTIMICROBIAL N-CHLORINATED COMPOSITIONS | NRDC, NHERF1, MPO | BBOX1 925/4885ENPP2 4656/4885 |
| US-20110190392-A1 | Polysaccharide Based Antimicrobial Formulations | FUT6, FUT5, OGT | BBOX1 807/4885ENPP2 2949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.